Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Relevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver, especially with steatosis

Fig. 4

FXR-agonist induced expression of SHP, showed adipogenic and adipolytic effects in hepatocytes, and protected steatotic hepatocytes. a Expression of SHP was induced by GW4064 (0.5 to 2.0 μM) 36 h after the treatment in AML12 liver cells. Each blot represents at least three independent experiments. The duplicates of immunoblots are taken from the specimens of experiments performed at different times. ImageJ software was used for quantitative analysis of western blot. b Steatosis was observed in AML12 liver cells by treatment with 1.0 and 5.0 μM of T0901317 (a specific agonist of LXR) for 7 days. The accumulation of TG induced by T0901317 was significantly suppressed by the concurrently administered GW4064 (1.0 μM). c The adipolytic and protective effects of GW4064 were evaluated by using LXR-induced steatotic hepatocytes. The treatment with T0901317 robustly reduced TG contents in a dose-dependent manner, and reduced cell death (LDH release) of the steatotic hepatocytes. Each experiment was performed three times and the data are expressed as mean ± SEM. p values of <0.05 were considered statistically significant

Back to article page